The $1.2 million injection is usually referred to as Achille’s Race Injection, a new type of immunotherapy that is currently only approved for certain hematologic malignancies, excluding pancreatic cancer. Akirense Injection is a type of chimeric antigen receptor T cell immunotherapy, or CAR-T therapy, which works by using gene editing technology to genetically edit the patient’s T cells so that they have the function of recognizing and killing tumor cells, and then the edited T cells are infused back into the patient’s body to provide anti-tumor effects. Akirenzai injection is currently approved for marketing in China, and its indication is for patients with relapsed or refractory adult diffuse large B-cell lymphoma after second-line or higher systemic treatment. The main indications for other CAR-T therapies are also mostly hematologic malignancies, while pancreatic cancer is a solid tumor and is not currently included in the indications for related therapies. If pancreatic cancer is suspected or diagnosed, it is recommended to go to a regular hospital to evaluate the condition and follow the doctor’s instructions for treatment to avoid delay. Please strictly follow the doctor’s instructions for medication, and do not use medication on your own.